Company Sector
10 companies tagged with Gene Therapy.
Gene Therapy includes companies delivering genetic material to correct, replace, silence, or modulate disease-driving biology. This sector page is useful for following businesses exposed to AAV, lentiviral, non-viral, or editing-enabled approaches across rare and broader diseases.
AMGN
Amgen is a large-cap biopharmaceutical company with a commercial base spanning oncology, inflammation, bone health, cardiovascular disease, and rare disease. Investors follow the stock for the mix of marketed products, late-stage pipeline optionality, and recurring regulatory or launch milestones.
CRSP
CRISPR Therapeutics is a gene-editing company with exposure to cell therapy and genetic medicine. Investors watch the company for how its editing platform broadens beyond the first commercial and clinical milestones.
EYEN
Eyenovia is an ophthalmology-focused biopharmaceutical company centered on eye-disease programs where clinical validation and specialty adoption drive the narrative.
EYPT
EyePoint Pharmaceuticals is an ophthalmology-focused biopharmaceutical company centered on eye-disease programs where clinical validation and specialty adoption drive the narrative.
GRPH
Graphite Bio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
FIXX
Homology Medicines is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
NTLA
Intellia Therapeutics is a gene-editing company focused on in vivo CRISPR-based medicines. Investors watch how the platform translates into durable clinical proof, delivery confidence, and a broader pipeline.
EYE
National Vision is an ophthalmology-focused biopharmaceutical company centered on eye-disease programs where clinical validation and specialty adoption drive the narrative.
SRPT
Sarepta Therapeutics is a genetic medicines company focused on neuromuscular disease, with investors watching how its RNA and gene-therapy programs translate into durable clinical and commercial value.
VERV
Verve Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
